CANTHER - "Hétérogénéité, Plasticité et Résistance des Cancers aux Thérapies"

Dr. Antonio MARAVER, Institut de Recherche en Cancérologie de Montpellier, interviendra sur le thème « Role of the Notch pathway in lung adenocarcinoma: beyond the KrasG12V mouse model. »

le 4 Juillet 2019 à 11h00 Amphithéâtre de l’Institut de Biologie de Lille.

(Campus de l’Institut Pasteur de Lille, 1 Rue Pr. Calmette LILLE, métro Lille Grd Palais).
Oncogenic addiction has been therapeutically exploited in a subset of lung adenocarcinoma patients harboring genetic alterations in different oncogenes such as EGFR, ALK,
MET, ROS, or RET, thanks to the development of tyrosine kinase inhibitor (TKIs). Although these patients have in general a good initial response they always develop
resistance by a plethora of mechanisms including new mutations, also called gatekeeper mutations.
Our group endeavors to tackle resistance to all these treatments in lung adenocarcinoma by combining the inhibition of oncogene addiction, trough the use of different
tyrosine kinase inhibitors, and of non-oncogen addiction, by using the Notch pathway as an example.

Adresse du Campus de l’Institut Pasteur de Lille, 1 Rue Pr. Calmette LILLE, métro Lille Grd Palais
Pour des mesures de sécurité, il est recommandé de vous inscrire par mail :  albin.pourtier@ibl.cnrs.fr